Center for Pediatric Oncology and Hematology

Center for Pediatric Oncology and Hematology

Pauline Allen Gill Center for Cancer and Blood Disorders

95+ clinical trials, 900+ annual patients, 1 amazing team

As the largest cancer and blood disease program in North Texas, and one of the largest in the U.S., Children’s Health℠ provides care for more than 350 children with newly-diagnosed cancer and more than 600 children with newly-diagnosed blood disease each year.

Children’s Health is the only pediatric cancer program affiliated with the UT Southwestern Harold C. Simmons Comprehensive Cancer Center. As the only National Cancer Institute-designated comprehensive cancer center in North Texas, we are always pushing to discover new treatments. We offer patients the ability to participate in the broadest possible range of clinical trials, giving access to potential therapies not available at other facilities.


Heart doctors at Children's Health analyze a patient's imaging results

UCART19 in Pediatric Patients with Relapsed/Refractory B Acute Lymphoblastic Leukemia

This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). Learn more

Conferences and Events

Many of our conferences and events offer continuing education credits.

Sign up for Upcoming CME

Latest News

ACE Program Celebrates Its 30th Anniversary

After the Cancer Experience (ACE) is the first and largest cancer survivor program in North Texas that bridges medical care from childhood to adult life within a centralized medical system. Learn more.

Theodore Laetsch, M.D., Recognized as a UT Southwestern Rising Star

Dr. Laetsch spearheaded the creation of the Experimental Therapeutics Program (ETP) at the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health. The program brings innovative therapies to children with a wide variety of cancers.

As the ETP’s Director, Dr. Laetsch serves as Principal Investigator of more than a dozen Phase I and Phase II trials of novel agents for children with relapsed or refractory cancer.

Meet the Care Team